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Abstract
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder characterized by
the loss of memory and behavior and represents the sixth leading cause of death in the USA.
Little is known about the brain’s transcriptome profile before the pathology of AD. Identifying
proteins that are differentially expressed at an early stage of AD may provide critical information
on biomarkers that contribute to disease progression. To perform these studies, we assessed
protein expression in hippocampal and cortical tissue samples from transgenic (TG) TgF344-AD
rats compared to wild type (WT) controls at a pre-pathology stage of four months, namely before
the detection of amyloid-β plaques or hyper-phosphorylated tau. In this regard, we compared
proteins that were differentially expressed. The results showed differences in increasing levels of
an active form of the matrix metalloproteinase (MMP-9) and the phosphorylation of extracellular
signal-regulated protein kinase (ERK) in the TG rats compared to their WT littermates. Previous
studies show that activation of the ERK pathway correlates with the progression of AD. Our
findings show that ERK signaling is increased in the pre-pathology stage, implicating ERK as a
signaling pathway that may contribute to the development of AD. In addition, the results show
increased levels of an active form of MMP-9 in the cortex of the transgenic brains compared to
the wild-type samples, suggesting an involvement of the immune response. The presence of
active MMP9 in TG rats during pre-pathology suggests that neuro-inflammation begins at an
early stage in the development of the disease. We then assessed whether drug therapy would alter
the expression of proteins that were expressed during pre-pathology using diazoxide (DZ), a
repurposed drug for hypertension. Drug repurposing is an alternate approach to treat AD. TG rats
treated DZ had increased expression of intermediate early proteins such as the Egr1/Arc pathway
which is responsible for neuronal survival, synaptic plasticity, and memory. These findings
2

suggest that drug treatment during pre-pathology may be effective in conferring neuroprotection
that could attenuate disease progression.
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Chapter I
Introduction
1.1

OVERVIEW OF ALZHEIMER’S DISEASE
Alzheimer’s disease (AD) is a form of neurodegeneration characterized by the loss of

memory, thinking, and behavior as an individual grows older. Biologically, there is a progressive
deposition of senile plaques and neurofibrillary tangles, along with oxidative stress which
induces a chain of inflammatory cascades. It starts to affect the locus coeruleus where the disease
arises years before the symptoms start becoming noticeable (Figure 1) [1]. It spreads to the
entorhinal cortex and hippocampus, where new memories are formed, and further to the
cingulate cortex and prefrontal cortex, where language and information processing occurs. There
is shrinkage of the brain, starting from the center of where the damage emerged, and soon the
brain is filled with cerebrospinal fluid.
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Figure 1. Regions of the brain. The neurons from the locus coeruleus project itself
throughout the brain. The blue arrow denotes the movement of noradrenaline, a
neurotransmitter released by neurons from the peripheral nervous system. Areas of the brain
that project the red arrows are regions that help to maintain the noradrenergic innervation from
the locus coeruleus [2]. The functional complexity of this system helps to modulate learning
and memory, and its dysregulation has been characterized in many neuropsychiatric and
neurodegenerative disorders. Areas boxed in red will be the focus of the experiments.

Neurofibrillary Tangles & Amyloid- β Plaques
Two of the main hallmarks of AD are (1) neurofibrillary tangles and (2) aggregates of
amyloid-β (Aβ) protein. There is no set of concrete evidence showing if neurofibrillary tangles
affect the production of amyloid-β plaques and vice versa. However, there is increasing evidence
showing that these two hallmarks interact to enhance AD.
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Tau proteins are part of the microtubule cytoskeleton that helps with the structure of the
neurons. When the tau protein is hyperphosphorylated, the phosphates repel one another,
disassembling the microtubules. The tau proteins form aggregates called neurofibrillary tangles
(NFTs) that lead to structural instability of the neurons, especially at the axon. The tau proteins
are phosphorylated by kinases such as cyclin-dependent protein kinase 5 (Cdk5) and glycogen
synthase kinase 3β (GSK3β) [3].
Plaques are derived from amyloid precursor protein (APP) which is cleaved in two ways:
non-amyloidogenic and amyloidogenic (Figure 2). Non-amyloidogenic processing involves αsecretase cleavage of APP to make an 83-amino acid protein, then γ-secretase cuts it further to
create Aβ-40 subunits. The product of the amyloidogenic pathway, created with β-secretase
instead of α-secretase, are highly hydrophobic Aβ-42 subunits that clump up into oligomers.
There needs to be a balance between the two secretases, so the 9:1 ratio of Aβ-40 to Aβ-42
production is preserved. This can become problematic when the ratio favors the formation of Aβ42 subunits, where these oligomers start to bind to the neurons, destroying the synapses, and the
amyloid burden becomes hard to remove once neurons start dying.
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Figure 2. APP processing in the brain [4]. APP is a transmembrane protein that can be
cleaved into two forms. In homeostatic conditions, 90% of APP is cleaved through the nonamyloidogenic pathway while 10% is processed through the amyloidogenic pathway. When
this homeostatic ratio is compromised and favors the formation of the Aβ oligomers, neuronal
damage at the synapses can be induced.
With the birth of the amyloid and tau hypothesis, β-secretase 1 (BACE-1) and tau kinases
have been popular targets for therapeutic intervention. Since BACE-1 leads to the production of
Aβ-42 monomers, it has been proposed to be a potential inhibitor to target for AD. BACE-1 has
a large active site that can be hard to pharmacologically inhibit. Even if there were a molecule to
inhibit this enzyme, finding a molecule permeable to the blood-brain barrier has been difficult to
create. Directly inhibiting BACE-1 has also led to impairment in synaptic plasticity and
cognition [5]. Cdk5 and GSK3β have been proven to phosphorylate tau in several papers.
However, knocking out Cdk5 kills mice perinatally, suggesting that it has an important role in
development while GSK3β inhibitors have not shown significant efficacy in clinical trials [5].
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Oxidative Stress and Inflammation
Mitochondrial dysfunction is well recognized to be involved in the pathogenesis of many
neurodegenerative disorders such as Parkinson’s, Alzheimer’s, and Huntington’s disease. The
mitochondria are the cell’s powerhouse and are essential for cellular function, ATP production,
and proper cell signaling. It also naturally generates reactive oxidative species (ROS), molecules
that are converted to free radicals, and are highly reactive due to their unpaired electrons in the
valence shell. However, this can be problematic when it passes homeostatic levels. Neurons
require large amounts of energy and are often metabolically active to function properly [6]. The
mitochondria in AD brains have reduced membrane potential, increased permeability, and excess
ROS which damages other cellular structures [7]. This oxidative stress leads to an activation of
inflammatory cascades that lead to apoptotic signals and the death of neurons when the
inflammation becomes chronic.
1.2 THE NEED FOR THERAPEUTIC INTERVENTION
AD does not only affect the person who is diagnosed with the disease, but also their
family members who have to experience the memory loss of their loved one. AD drugs have a
99% failure rate because of the difficulty and costliness of creating new drugs that are specific to
alleviating the symptoms of AD, especially when this is a progressive disease; once the neuron is
damaged, it is very unlikely for it to regain its function [8]. Many biotechnology companies, such
as Pfizer and Johnson & Johnson, have stopped funding for the development of AD drugs
because of its failure rates in drug efficacy in the recent clinical trials. There is also no diagnostic
test to detect if someone is developing the disease. Research on biomarkers for the disease and
other forms of dementia can also greatly reduce the further onset of the disease.
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Upon the high percentage of drug failures, scientists have recently tried a new approach:
repurposing FDA-approved drugs. This offers an expedited and economical route since clinical
trials are often time-consuming and costly [9]. Using the similarities between diseases, such as
inflammation and its role in pathogenesis in both cancer and neurodegenerative disease, drugs on
the market can be used to treat similar symptoms in other diseases.
Diazoxide
Diazoxide (DZ) is a potassium channel activator drug used for hypertensive purposes. Its
main purpose is to enhance the membrane permeability to potassium ions, which inhibits the
generation of an action potential in local smooth muscles to relax it. It also prevents neuronal
oxidative stress by reducing intracellular ROS and serving as a neuroprotectant. The drug has
been shown to decrease neuronal apoptosis and increase astrocyte survival by inducing higher
levels of Bcl-2, an anti-apoptotic protein, and inhibiting Bax, an executor protein, from leading
the cells to an apoptotic faith [10]. DZ was used in our studies to address its effect on gene
expression during pre-pathology in rats transgenic for AD.
1.3 SIGNIFICANCE
Based on the 2019 statistics from the National Institute of Health, AD is ranked as the
sixth leading cause of death in the USA [11]. AD is irreversible since damaged neurons in the
central nervous system (CNS) cannot regenerate as readily as other cells in the body and
therefore the number of neurons we are born with is what we have to work with. The progressive
loss of neurons, starting from the hippocampus, slowly destroys cognitive functions such as
memory, thinking, and reasoning. When the disease becomes severe, a person’s daily life and
activities become unfamiliar to the point where they must be dependent on others. It is believed
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that detecting the development of the disease at an early stage would prevent the loss of a
significant number of neurons.
For these reasons, in this study, gene and protein expression of rats pre-pathology for AD
were studied, compared to their wild-type littermates, to detect any differences that can lead to
the onset of the disease. After receiving RNA-sequencing data, further experiments were
performed on a select number of genes to confirm the same change at the protein levels. Such
genes play various roles in the cell adhesion (E-cadherin), the immune response and degradation
of the extracellular matrix (MMP-9), act as a transcription factor (Fos and FosB), regulate
synaptic plasticity (Arc), and encode for immediate early genes (Egr1 and Egr2). Treatment with
diazoxide reverses the expression levels of these genes, which signifies that the drug is helping to
revert the gene expression profiles to be similar to the wild-type profile and hopefully reduce any
changes that could be leading to the onset of AD.
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Chapter II
Gene Expression Profile of AD Brains
2.1

INTRODUCTION
RNA-Sequencing (RNA-Seq) applies Next-Generation sequencing technology on RNAs

to allow for analysis of the expression of thousands of genes simultaneously. Three different sets
of brain samples were sent to UCLA Technology Center for Genomics & Bioinformatics for
RNA-Seq analysis. These sets include the left hippocampus from 4-month-old untreated wildtype (WT), untreated transgenic (TG), and diazoxide-treated TG rats. After receiving the
hippocampal tissue samples, mRNA is isolated, reverse transcriptase is added for first-strand
synthesis of cDNA, and then a cDNA library is created through amplification of the genes with
the use of adaptors. Once the genes are amplified and the machine readings are transferred to the
computer, scientists can perform software analysis and create heat maps to visually show which
genes are being up- or down-regulated and how these genes can be further connected. The RNASeq studies were a comparison of gene expression analysis of rat hippocampal tissue and by
Western blot analysis of cortical tissue to perform a protein expression analysis. Two
comparisons were made: (1) wild-type untreated against transgenic untreated and (2) transgenic
untreated versus transgenic treated with diazoxide (DZ).
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2.2

RESULTS
The tables show a portion of the genes that are differentially expressed within two

particular groups. They were selected based on their significant P-value and cellular function.
Table 1 shows a comparison of untreated transgenic (TGU) rats to untreated wild-type (WTU)
rats. RNA-Seq analysis confirmed the double mutation in the TGU rats from the 1.985367x and
2.1131x fold increase in gene expression of APP and PSEN1, respectively, when compared to
WTU rats (Table 1). This is expected since the TGU rats, not the WTU rats, overexpress these
genes. Treatment with diazoxide (TGZ) switched the gene expression profiles whereas anything
upregulated in TGU vs. WTU is now downregulated in TGZ vs. TGU and vice versa (Table 2).
Diazoxide (DZ) has no effect on APP and PSEN1, as the ratio is one or slightly lower (-1) (Table
2). The genes for E-cadherin and MMP9 are upregulated in TGU rats and downregulated by DZ
while Egr1 and Egr2 are downregulated in TGU rats and upregulated by DZ (Tables 1 and 2).
The Arc gene is equally expressed in the TGU and WTU rats and therefore it is not shown in
Table 1. The difference in Arc gene expression only appeared when the rats were treated with
DZ (Table 2).
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Tables 1-2: RNA-Seq data analysis between designated genotypes. Downregulated genes
are colored in green while upregulated genes are colored in red.
Table 1: Transgenic Untreated (TGU) vs. Wild-type Untreated (WTU).
Table 2: Transgenic Treated with Diazoxide (TGZ) vs. Transgenic Untreated (TGU).
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Chapter III
Protein Analyses of RNA-Seq Genes Reveal Changes in
Protein Expression Consistent with RNAseq Analysis
3.1

INTRODUCTION
A long list of genes was given, however a select few will be mentioned in this paper.

Only hippocampi gene expression was compared by RNA-Seq analysis. While gene expression
differences are significant, it is also important to evaluate if this difference in gene expression is
also shown at the protein level. Therefore, Western blot analyses on the same group of rats were
performed to confirm the changes seen in the RNA-Seq analysis. In these analyses, protein
expression was compared to the prefrontal cortex (PFC), cingulate cortex (CC), and entorhinal
cortex (EC). The EC is the closest region to the hippocampus and the PFC is the farthest.
Cadherins
Cadherins are synaptic cell adhesion molecules (CAMs) that accumulate at the synapse to
mediate interactions between cells and regulate synaptic plasticity. Research has shown that
cadherins may interact with amyloid-β plaques in Alzheimer’s, which can affect the expression
of CAMs and synaptic interactions between neurons, leading to synaptic loss and impairment
[12]. There has been increasing evidence of a relationship between presenilin 1 (PSEN1) and Ecadherin. PSEN1 is a protein that localizes at the synapse and stimulates amyloid-β production. It
is necessary for late development since PSEN1 -/- mice die shortly after birth with skeletal
impairments and impaired neurogenesis [13]. PSEN1 has been shown to perform a γ-secretaselike cleavage of E-cadherin and N-cadherin, which could start a signaling cascade to impact the
20

gene expression [14]. This kind of cleavage of E-cadherin causes disassembly of cadherin-based
adherens junctions from the cytoskeleton, which normally promotes cell-cell adhesion through
calcium-dependent interactions [15].
Egr1 and Egr2
Early growth response-1 (Egr1) is one of the four genes in the EGR family of immediate
early genes (IEGs). Early growth response-2 (Egr2) is an inducible transcription factor, along
with c-FOS, FosB, and c-JUN. There have been very few studies on Egr2 and its possible roles
in AD. It has been hypothesized that Egr2 and Egr1 are possible targets of nuclear factor kappa B
(NF-κB), which is a transcription factor that has been known to be activated in neurons and
astrocytes by Aβ peptides since Egr1 has a binding sequence for NF-κB in its promoter region
[16] [17].
While an Egr2 knock out is lethal, mice lacking Egr1 is viable and not necessary for
prenatal development. However, Egr1 is required for postnatal development, in the case of
synaptic formation in the cortical and hippocampal regions. It is then expressed at basal levels
throughout the brain for the remainder of the mice’s life. Egr1 mutant mice have intact shortterm memory, but their long-term memory is drastically impaired, indicating its importance in
the hippocampal region of the brain [18]. Outside factors such as stress, early life experiences,
and social experiences impact the expression of Egr1 via the activation of mitogen-activated
protein kinase (MAPK) pathways. This increase in Egr1 has been shown to affect synaptic
plasticity that involves memory, addiction, and anxiety [19]. Post-mortem studies of brains from
AD patients show that Egr1 is upregulated in the cortex and hippocampus regions [17].
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Egr1 impacts both hyper-phosphorylation tau and amyloid-beta production in a separate
manner [5]. In terms of neurofibrillary tangles, Egr1 affects GSK3-beta indirectly and does so by
activating Cdk5 via p35 transcription. Inhibiting Egr1 would prevent p35 transcription, which
would prevent priming of GSK3β, and finally reduce tau phosphorylation on Ser235 and Thr231.
In terms of Aβ plaque buildup, Egr1 stabilizes the expression of BACE-1, leading to the
amyloidogenic cleavage of amyloid-β. Inhibiting Egr1 would decrease transcriptional levels of
BACE-1 and do not affect α-secretase, increasing the likelihood of having more Aβ-40 subunits
than Aβ-42 subunits. Egr1 is also shown to improve cognition amongst these mice and does not
cause any major developmental deficits. These results further prove that Egr1 is a potential
therapeutic candidate for AD treatment.
MMP-9
Matrix metalloproteinases (MMPs) are calcium-dependent endopeptidases present in the
extracellular matrix (ECM) to degrade several molecules directly or indirectly through signaling
molecules. They play an important role in CNS development, synaptic plasticity and
reorganization, and blood-brain barrier integrity. Some MMPs play a role in the inflammatory
response in the brain, which allows it to be considered as a potential biomarker to detect AD
from an early stage since it can be detected in the plasma or serum [20]. MMPs degrade the
ECM in normal and pathological conditions. It is also known to activate neuroinflammatory
pathways by cleaving certain cytokines, cell surface receptors, and cell-cell adhesion molecules
during neuroinflammation and can permeabilize the blood-brain barrier with its protease activity
[20].
MMP-9, which encodes for gelatinase B, is one of the most studied MMPs. It is found to
be localized in neurons near the synapse and glial cells, specifically astrocytes. MMP-9 is also
22

crucial for the development of the CNS, where its expression peaks during early development
and it remains low during adulthood [21]. The release of MMP-9 at the synapse is dependent
upon the neuronal activity, as it cleaves synaptic cell-adhesion molecules and reorganizes the
excitatory synapses on the dendritic spines. This is also where the MMP-9 mRNA is present.
MMP-9 activity increases after performing activities assessing spatial learning, such as the
Morris water maze test. This indicates MMP-9 might have a role in the synaptic remodeling of
the hippocampus concerning learning and memory [21]. In addition, several papers have
mentioned it to be a neuroprotective factor that helps to facilitate the cleavage of APP by acting
like α-secretase [22] [23]. However, further studies must be done to prove how this mechanism is
performed in the brain and how it can be applicable to AD. Based on observations so far, MMP9 has been detected in amyloid plaques and there are higher levels of MMP-9 protein in the
hippocampus of AD mice controlled to the control mice, using the 5xFAD mouse model [20].
There are also increased levels of MMP-9 mRNA and protein in postmortem brains from AD
patients [20].
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3.2

RESULTS

3.2.1 Protein analyses of differential genes in the cortex of AD brains.
RNA-Seq analysis of hippocampi from TG rats have shown an upregulation in gene
expression of E-cadherin (1.7965x) and downregulation in gene expression of Egr1 and Egr2 (1.49372x and -2.02001x respectively) (Table 1). However, Western blot analyses of the PFC,
CC, and EC regions show that the untreated wild-type (WTU) and untreated transgenic (TGU)
rats exhibit the same levels of E-cadherin, Egr1 and Egr2 (Figure 3). Unfortunately, protein
analyses were not performed on the hippocampus which was used for the RNA-Seq analysis.
3.2.2 Upregulation of an active form of MMP9 in the cortex of AD brains.
The RNA-Seq data show that MMP-9 is upregulated by a fold change of 1.649439 in the
hippocampi of untreated TG rats compared to the wild-type untreated samples (Table 1). The
MMP-9 polyclonal antibody used for this Western blot analysis detects 4 bands: a 92-95 kDa
band which represents the pro-form and three other bands at 82, 67, and 64 kDa which are the
active forms. The 82 kDa band is a form of MMP-9 following processing by MMP-3. MMP-9 is
also known to have domains for N- and O- glycosylation and form complexes with other
molecules, which could explain the higher molecular weight bands. There is no significant
difference in the MMP9 pro-form (Figure 4C) however, there is a significant increase in the 67
kDa band in TGU samples in comparison to the WTU samples (Figure 4D). This increase in the
protein levels of the active form of MMP9 closely reflects the upregulation of gene expression
from the RNA-Seq analysis.
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Figure 3. Protein analyses of differential genes in the cortex of AD brains. Comparison
between the entire cortex region of wild-type untreated (WTU) and transgenic untreated
(TGU) brains. Lysates were analyzed with a western blotting procedure, probing with
antibodies for pan cadherin, Egr2, and Egr1. Actin was probed as a loading control. (A)
Representative Western blots. (B-D) Quantification of A, performed using ImageJ and
GraphPad Prism 8. Data are expressed as means ± SEM. N = 5 rats per genotype.

25

Figure 4. Upregulation of an active form of MMP9 in the cortex of AD brains.
Comparison between the entire cortex region of wild-type untreated (WTU) and transgenic
untreated (TGU) brains. Lysates were analyzed with a western blotting procedure, probing
with a polyclonal antibody for MMP-9. Actin was probed as a loading control. (A)
Representative Western blots. (B-E) Quantification of A, performed using ImageJ and
GraphPad Prism 8. Data are expressed as means ± SEM. N = 3 rats per genotype. **P ≤ 0.01
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Chapter IV
Activation of the ERK Signal Transduction Pathway in the
Pre-Pathology Stage of AD Brains
4.1

INTRODUCTION
Cells respond to changes in the extracellular environment and intrinsic stimuli through

various cell signaling cascades. Receptors in the cell membrane recognize signaling molecules,
such as neurotransmitters in the case of the brain, and initiate a phosphorylation cascade of
proteins specific to the stimuli received. This cascade can ultimately regulate gene expression
through the induction of transcription factors. Research has proven crosstalk is possible amongst
different types of signal transduction pathways. Targeting certain molecules in these pathways
are possible therapeutic approaches as they can help to regulate gene expression to reduce the
risk of certain diseases. Thus, further analysis of the RNA-Seq data was conducted and it linked
the genes to three main signaling cascade pathways: JNK, mTOR/Akt, and ERK pathway.
JNK Pathway
The stress-activated protein kinase/Jun-amino-terminal kinase (SAPK/JNK) pathway
controls cellular processes such as embryonic development and apoptosis. The main players of
this pathway include the c-Jun N-terminal kinases 1-3 (JNK1-JNK3), who are the MAPKs that
interact with several transcription factors that would help lead the cell to a certain fate. Mitogenactivated kinase kinase-4/7 are upstream activators of JNK. JNK1-3 helps to maintain the
physical and regulatory functions of the CNS, involved in long-term potentiation. Recent
research has shown that it enhances amyloid-β production because the pathway has been known
27

to be upregulated in the post-mortem brains of AD patients and JNK is co-localized in areas with
high concentrations of amyloid-β [24] [25]. JNK is considered to be a stress kinase that is a
degenerative effector of signal transduction cascades, where it can inhibit the activity of antiapoptotic proteins, such as Bcl-2 and Bcl-XL, by phosphorylating them, and finally leading to
the activation of caspases [26].
AKT/mTOR Pathway
The PI3K/AKT/mTOR pathway consists of three main players: (1) Phosphoinositide 3kinase (PI3K), protein kinase B (Akt), and the mammalian target of rapamycin (mTOR). Akt is a
proto-oncogene involved in the metabolism, growth, proliferation, and survival of cells.
Amyloid-β was shown to induce hyper-phosphorylation of Akt and mTOR, and their
downstream regulators, p70S6K and p4E-BP1 [27]. It has also been shown that increasing doses
of Aβ oligomers displayed dose-dependent-increase in mTOR hyperactivity [28]. The
mechanism of action for this pathway involvement in AD is that mTOR leads to dysfunctional
autophagy, which is one of the cell’s defense mechanisms to get rid of abnormally aggregated
proteins and degrade organelles to make room for new ones. Since this process is no longer
working as it should, Aβ oligomers accumulate at the synapse while P60S6K hyperphosphorylate tau, along with GSK3β [29]. GS3Kβ is well-known to be involved in the process
of hyper-phosphorylating tau in AD pathology with Akt as its upstream regulator. Due to this
connection to AD and the interaction between the Akt/mTOR and Akt/GS3Kβ pathways, the
AKT pathway has been a target of interest for therapeutics.
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ERK Pathway
The extracellular signal-regulated kinases (ERK1/2) are involved in a variety of cellular
functions through MAPK and ERK signaling cascade. This signaling pathway involves a chain
of protein signaling from the receptor on the surface of the cell to control DNA transcription
machinery through the regulation of transcription factors in the nucleus. Such changes in the
transcription of certain genes via the MAPK/ERK pathway can induce changes in cell division,
adhesion, migration, and death. MEK1/2, a mitogen-activated protein kinase kinase,
phosphorylates ERK1/2 on its regulatory threonine 202 and tyrosine 204 residues. Activated
ERK1/2 can then translocate to the nucleus to target transcription factors such as c-FOS and cJUN. c-FOS, along with Arc and Egr1, are under a family of IEGs which regulate neuronal
activity and are associated with learning and memory processes. The c-FOS proto-oncogene
encodes for a Fos protein that dimerizes with c-JUN to make further changes to gene expression.
c-FOS is often expressed in areas where action potentials are present, making it a useful
candidate for studying drug abuse. However, the specific role of c-Fos in memory and learning is
unclear as it requires more research.
The ERK pathway is activated in the neurons of AD patients, suggesting they could be
involved in the pathology of the disease and could be a potential therapeutic target of treatment
[30] [31]. Studies have shown that APP expression enhances ERK signaling and GSK3β
activation, which are both known to phosphorylate tau and induce APP itself [32]. ERK
activation correlates with oxidative stress, one of the mechanisms that impact the progression of
AD [33]. As important as ERK1/2 is for normal development and proper neuronal plasticity,
abnormal ERK activation with aging can impair certain brain functions as it contributes to βamyloid neurotoxicity.
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4.2

RESULTS

4.2.1 Signaling pathways involved in the development of AD pathology.
The antibody for Phospho-Akt was chosen specifically to detect any changes in the
mTOR pathway. Phosphorylation of Akt at Ser473 has been indicative of the activation of the
mammalian target of rapamycin (mTOR) pathway since the mammalian target of rapamycin
complex 2 is known to be one of the kinases that phosphorylate Akt at that amino acid site [34].
However, phosphorylated and total protein levels both Akt and JNK are generally the same
between the WTU and TGU lysates (Figure 5). The lack of activation of these two pathways is
implicative of their involvement in the early stage of AD, as they are not involved in the early
progression of the disease but rather in accelerating the hallmarks of the disease when they
emerge in older rats.
4.2.2 Upregulation of ERK phosphorylation in the cortex of AD brains.
Probing for p-ERK and t-ERK revealed significant upregulation of ERK phosphorylation
in the AD cortex compared to the WT cortex (Figure 6B and 6C). To further analyze how the
ERK pathway is activated, c-FOS was chosen as a candidate from RNA-Seq analyses as Fos and
FosB are downregulated with a fold change of 1.12805 and 1.31183, respectively in TGU brains
compared to the WTU (Table 1). Consistent with these findings, Western blot analyses show that
there are no significant differences between TG and WT rats in c-FOS expression (Figure 6D).
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Figure 5. Signaling pathways involved in the development of AD pathology. Comparison
between the entire cortex region of wild-type untreated (WTU) and transgenic untreated
(TGU) brains. Lysates were analyzed with a western blotting procedure, probing with
antibodies for p-AKT (Ser473), t-AKT, p-JNK, and t-JNK. Actin was probed as a loading
control. (A) Representative Western blots. (B-E) Quantification of A, performed using ImageJ
and GraphPad Prism 8. Data are expressed as means ± SEM. N = 5 rats per genotype.
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Figure 6. Upregulation of ERK phosphorylation in the cortex of AD brains. Comparison
between the entire cortex region of wild-type untreated (WTU) and transgenic untreated
(TGU) brains. Lysates were analyzed with a western blotting procedure, probing with
antibodies for p-ERK, and t-ERK, and c-FOS. Actin was probed as a loading control. (A)
Representative Western blots. (B-D) Quantification of A, performed using ImageJ and
GraphPad Prism 8. Data are expressed as means ± SEM. N = 4 rats per genotype. **P ≤ 0.01
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Chapter V
Differential Effect of Diazoxide in Transgenic AD Rats
5.1

INTRODUCTION
The Arc gene is an IEG that encodes for an activity-regulated cytoskeletal (Arc) protein,

a master regulator of synaptic plasticity. Unlike other IEGs, such as c-FOS and Egr1, Arc
encodes for a synaptic protein instead of a transcription factor. After its translation, Arc mRNA
is transported to the axon where it is translated to protein, which self-assembles into virus-like
capsids to mediate the transfer of Arc mRNA into new target cells [35]. Therefore, the
postsynaptic dendrites are enriched with more Arc mRNA compared to the presynaptic axons
after a signal is sent from one neuron to another, earning Arc’s involvement as a marker for
neuronal activity. It is also involved in regulating learning and memory as it is upregulated in
sub-regions of the brain that specialize in this, such as the hippocampus [19]. Egr1 has also been
shown to regulate Arc activity [19]. In Huang Fen et al., scientists explored how activity in the
actin network and MAPK activation affects Arc mRNA localization. They found out that
inhibition of ERK phosphorylation, in comparison to other MAPK signaling pathways, blocked
the localization of the Arc mRNA to the axon. Reorganization of the actin cytoskeleton and ERK
activation are required to get Arc mRNA to the dendritic shaft and onto the activated synapse
[36].
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5.2

RESULTS

5.2.1 Drug-induced increase of the Egr1/Arc pathway in the cortex of AD brains.
The relationship between Egr1, Arc, and ERK phosphorylation was further explored as
there was a drug-induced upregulation of Arc in all three of the cortex regions of the transgenic
brains treated with diazoxide (TGZ) compared to the untreated transgenic brains (TGU) (Figure
7F). While the increase in Arc was significant, significance was not shown for Egr1 due to high
standard error bars. This effect presumably can be resolved with further experiments (Figure 7E).
However, the pattern of higher Egr1 and Arc protein levels are conserved through all three
regions of the cortex when the rats were treated with diazoxide (Figure 7E and 7F).
5.2.2 Diazoxide response to ERK phosphorylation is specific to the prefrontal cortex of
AD brains.
ERK phosphorylation was only increased in the prefrontal cortex in the drug-treated rats
(Figure 8E and 8F) while the levels of total ERK remained the same in all three regions of the
cortex (Figure 8G and 8H). This signifies that ERK signaling is more sensitive to the drug in the
PFC region of the brain, compared to the other regions.
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Figure 7. Drug-induced increase of the Egr1/Arc pathway in the cortex of AD brains.
Comparison between the three separate regions of the cortex from transgenic untreated (TGU)
and transgenic treated with diazoxide (TGZ) brains. Lysates were analyzed with a western
blotting procedure, probing with antibodies for Egr1 and Arc. Actin was probed as a loading
control. (A-C) Representative Western blots. (E-F) Quantification of A-C, performed using
ImageJ and GraphPad Prism 8. Data are expressed as means ± SEM. N = 3 rats per genotype.
*P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001
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Figure 8. Diazoxide response to ERK phosphorylation is specific to the prefrontal cortex
of AD brains. Comparison between the three separate regions of the cortex from transgenic
untreated (TGU) and transgenic treated with diazoxide (TGZ) brains. Lysates were analyzed
with a western blotting procedure, probing with antibodies for p-ERK and t-ERK. Actin was
probed as a loading control. (A-C) Representative Western blots. (E-H) Quantification of A-C,
performed using ImageJ and GraphPad Prism 8. Data are expressed as means ± SEM. N = 3
rats per genotype. *P ≤ 0.05 and **P ≤ 0.01
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Chapter VI
Discussion
In this study, we hoped to identify a biomarker that precedes the onset of AD by
analyzing the protein levels on cortical samples from transgenic AD (TGU) and wild-type
(WTU) rats at the pre-pathology stage of four months of age relative to parallel gene expression
analyses. When compared to WT rats, the RNA-Seq analyses showed that the upregulated genes
were E-cadherin and MMP-9 while the downregulated genes were Egr1 and Egr2. After protein
analyses, the upregulation of an active form of MMP-9 in the cortex is consistent with the RNASeq results of hippocampal tissue. In addition, there is a significant increase in the
phosphorylation and thus activation of ERK. These changes during pre-pathology reflect the
groundwork for disease progression as it represents the beginning of signal transduction cascades
that can enhance the development of major biological hallmarks.
The pan cadherin antibody recognizes a variety of cadherins and was chosen to identify
changes with different cadherins that function in the brain. Studies have implicated E-cadherin
and N-cadherins in AD. In future studies, antibodies specific for each type of cadherin would
provide a better assessment of their expression levels. Cadherins are very important in cell-cell
communication, which is impaired between neurons in AD due to Aβ plaques.
While the downregulation of gene expression of both Egr1 and Egr2 is significant in the
hippocampus in transgenic rats, the protein analyses in the cortex show no difference between
the genotypes. Studying the expression and protein levels of IEGs throughout the pathology of
AD in the rats would be interesting to see if the changes in gene expression during pre-pathology
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are maintained during disease progression. Also, Egr1 and Egr2 are targets of NFkB, a key
player in the pathology of AD as it is activated in neurons and astrocytes by Aβ [16].
MMP-9 plays a role in the immune response in the brain and it is detectable in the blood,
which makes it a likely candidate for a potential biomarker. While it should peak during early
development and remain low for the result of adulthood, studies have shown an upregulation of
MMP-9 mRNA in post-mortem studies of AD brains. While the pro-form of MMP-9 showed no
significant difference, the active form of MMP-9 at 67 kDa was significantly upregulated in the
cortex of the transgenic rat samples. MMPs are secreted as inactive proteins until they are
proteolytically cleaved by an enzyme into its active form. In this case, a certain enzyme is
upregulating the cleavage of MMP-9 to a 67 kDa protein in the cortex of the TGU brain samples
[37]. The higher MW forms of MMP-9 detected in our studies may be due to glycosylation. In
other studies, the higher molecular weight bands for MMP9 were MMP-9 complexes with other
subunits with the 150 kDa and 125 kDa bands corresponded with an MMP9/TIMP1 and
MMP9/NGAL complex, respectively [38]. To confirm if our bands correlate with the ones in the
research paper, the lysates should be resolved by using a non-denaturing gel and then probing the
blots with the MMP-9 antibody.
The activation of the ERK pathway is not new to the pathology of AD. However, this
upregulation is detected at pre-pathology and can be the baseline for the initiation of signaling
cascades leading to the progression of AD. While there were no changes in the protein levels of
c-FOS, a downstream factor of ERK1/2, the pathway may be working through the regulation of
other transcription factors.
This study also addressed the use of repurposed drugs to alter gene expression that may
promote AD progression. Treatments with diazoxide showed a significant drug-induced
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upregulation in the protein expression of the Egr1/Arc pathway in the cortex region of transgenic
rats. The protein levels of Egr1 and Arc were significantly higher in all three regions of the
cortex examined. The high activity of these two IEGs can indicate an upregulation of neuronal
activity that can be manipulated by changing membrane permeability to potassium ions. As a KATP channel activator, diazoxide has been shown to help potassium ions flow into the
mitochondria and thus resulting in depolarization [39]. Research has shown that depolarization
of postsynaptic neurons can activate the cell’s machinery to induce gene expression through
several transcription factors, including IEGs, as a response to the increased concentration of
cytoplasmic calcium in the cells [40]. However, the mechanism as to how potassium channel
activators and IEGs are related is yet unclear in the literature and further experiments would be
required. Since literature has mentioned the upregulation of Egr1 and activation of the ERK
pathway in the pathogenesis of AD, Arc can be another key player in that pathway as it is a
protein that is under the regulation of Egr1 and is important for maintaining synaptic plasticity.
Synaptic activity is essential to the survival of neurons as the transfer of messages between
neurons could induce the activation of pro-survival genes and allow for local ATP synthesis. The
protective mechanism of diazoxide in this rat model for AD is evident early on, at pre-pathology,
to enhance synaptic activity. This could allow the neurons to better withstand the consequences
of the biological hallmarks of AD that will develop later on in the rat’s life.
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Chapter VII
Future Directions
As this is an ongoing project, it would be interesting to follow up on these genes in 11month old rats, which is when they start to show signs of pathology. Additionally, further
analysis of the AKT/mTOR pathway in 4-month old rats, with and without the treatment of
diazoxide, can provide further insights on the potential crosstalk between the ERK and AKT
pathway before signs of the disease even start. Along with the data shown above, it would be
interesting to see the protein levels of these genes in the hippocampi samples since the RNA-Seq
data was from the left hippocampus and the hippocampus is a key region in the progression of
Alzheimer’s.
Mitochondrial dysfunction and deregulation of the ubiquitin-proteasome pathway would
be other mechanisms that require attention since they may contribute to changes in gene
expression. While Alzheimer’s is a disease of improperly folded proteins, gene expression is also
important in that it is the ultimate result of many signaling pathways that act together to either
promote disease progression or rescue neurons from cell death.
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Chapter VIII
Methodology
8.1

MATERIALS

Primary antibodies: Pan cadherin (1:10000, Abcam, reference number ab51034, Cambridge,
MA, USA), EGR1 (1:1000, Cell Signaling Technologies, reference number #4153, Danvers,
MA, USA), EGR2 (1:5000, Abcam, reference number ab108399, Cambridge, MA, USA),
Phospho-Akt (Ser473) (D9E) (1:800, Cell Signaling Technologies, reference number #4060,
Danvers, MA, USA), Akt (pan) (C67E7) (1:1000, Cell Signaling Technologies, reference
number #4691, Danvers, MA, USA), Phospho-JNK (G-7) (1:800, Santa Cruz Biotechnology,
reference number #6254, Santa Cruz, CA, USA), SAPK/JNK (1:1000, Cell Signaling
Technologies, reference number #9252, Danvers, MA, USA), c-FOS (1:4000, Abcam, reference
number ab190289, Cambridge, MA, USA), Phospho-P44/42 MAPK (ERK1/2) (Thr202/Tyr204)
(1:1000, Cell Signaling Technologies, reference number #9101, Danvers, MA, USA), P44/42
MAPK (ERK1/2) (1:10000, Cell Signaling Technologies, reference number #9102, Danvers,
MA, USA), MMP-9 (1:1000, Abcam, reference number ab38898, Cambridge, MA, USA), Arc
(1:1000, Abcam, reference number ab183183, Cambridge, MA, USA), β-Actin (1:20000, SigmaAldrich, reference number #A2228, St. Louis, MO).
Secondary antibodies: Anti-mouse IgG HRP-linked (1:5000, Cell Signaling Technologies,
reference number #7076, Danvers, MA, USA), Anti-rabbit IgG HRP-linked (1:5000, Cell
Signaling Technologies, reference number #7074, Dancers, MA, USA)
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8.2

ANIMAL MODEL

All rats used in these studies were female wild-type Sprague Dawley rats or transgenic TgF344AD rats. They were ordered from Rat Resource & Research Center (RRRC) in Columbia, MO.
The TgF344-AD rat model exhibits a full array of AD pathological features. It expresses human
APP with the Swedish mutations, which is a double mutation that increased abnormal cleavage
of cellular APP by BACE, and a human PSEN1 with the delta 9 mutation, which helps to
increase higher levels of amyloidogenic proteins. Both genetic modifications are driven by a
mouse prion promoter. There is an age-dependent accumulation of amyloid plaques occurring in
the hippocampus and cortex between 6 and 26 months. Tau pathology is also observed with the
presence of neurofibrillary tangle-like structures. There is about 40% neuronal loss by 16 months
of age, compared to the wild-type animals [41]. The integration of the double mutations was
confirmed through the expression levels of APP and PSEN1 in the RNA-Seq data.
8.3

SURGERY, DRUG TREATMENT, AND DOSAGE

A subset of the transgenic rats was treated with diazoxide at around two months, while they are
in the pre-pathology stage for Alzheimer’s. Diazoxide (DZ) was shipped from MedChemExpress
in New Jersey and was fed to the rats daily at 10mg/kg in chow. After surgery, the tissues were
dissected from the brain and flash frozen on dry ice and then stored at -80 degrees in preparation
to be sent for RNA-Seq analysis.
8.4

RNA-SEQUENCING DATA

Hippocampi samples from wild-type untreated, transgenic untreated, and transgenic rats treated
with diazoxide were sent to UCLA Technology Center for Genomics & Bioinformatics for
RNA-Sequencing analysis. A few sample sets of the left hippocampus from each of the rats were
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subjected to RNA extraction with ribosomal depletion. There were a total of 13 tissue samples as
follows: 5 untreated wild-type rats (WTU), 5 untreated transgenic rats (TGU), and 3 transgenic
rats treated with diazoxide (TGZ) for a total of three groups. The gene expression for each of the
groups treated with drugs will be compared to that of the untreated group.
8.5

PROTEIN EXTRACTION AND WESTERN BLOTTING

Frozen tissue samples were added to BeadBug microtubes with a lysis buffer composed of 1X
TBS buffer and protease/phosphatase cocktail inhibitor. The samples were homogenized using
the BeadBug Microtube Homogenizer machine. It was then transferred to a microcentrifuge tube
where NP40, SDS, and glycerol were added. The samples were stored in -80C overnight and
were subjected to centrifugation the day after. After collecting the supernatant, the sample was
further purified through a BioMasher homogenizer and spun down for a clean lysate. Protein
concentrations were determined using a bicinchoninic acid assay (BCA). Afterward, equal
amounts of protein were loaded onto 4-12% Bis-Tris gels under the MOPS buffer system and ran
at 180V for 60 minutes before transfer onto a nitrocellulose membrane using the iBlot system.
The membrane was then blocked for an hour before washing and overnight incubation with the
primary antibody at 4C. Antibody binding was observed after incubation of the HRP-linked,
anti-rabbit secondary antibody for 45 minutes, followed by a series of washes, and then detection
with chemiluminescent substrates.
8.6

STATISTICAL ANALYSES

Quantification of Western blots was generated by ImageJ. Graphs and statistical analyses were
performed on GraphPad Prism 8. Data are expressed as means ± SEM. The sample size (N) is
denoted under each figure. Statistical significance was calculated using unpaired t-tests, one-
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way, or two-way ANOVA when applicable. Significance is denoted as the following P-values:
*P ≤ 0.05, **P ≤0.01, ***P ≤0.001, ****P ≤0.0001
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